Experimental Study: Presentation of Quantitative Effectiveness Information to Consumers in Direct-to-Consumer (DTC) Television and Print Advertisements for Prescription Drugs
Experimental Study:
Presentation of Quantitative Effectiveness Information to Consumers
in Direct-to-Consumer (DTC) Television and Print Advertisements for
Prescription Drugs
New
collection (Request for a new OMB Control Number)
As a reminder,
this study should not begin before 9/1/2010 due to the moratorium
on household surveys that is in place for the Census.
Inventory as of this Action
Requested
Previously Approved
06/30/2013
36 Months From Approved
13,500
0
0
1,755
0
0
0
0
0
The FDCA requires manufacturers,
packers, and distributors who advertise prescription human and
animal drugs, including biological products for humans, disclose in
advertisements certain information. FDA has an interest in
fostering safety and proper use of prescription drugs, an activity
that engages both risks and benefits, therefore an examination of
ways to improve consumers' understanding of this information is
central to this regulatory task.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.